We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

UARK 2009-32 Compassionate Use Study of Carfilzomib (2009-32)

Expanded access is no longer available for this treatment.
ClinicalTrials.gov Identifier:
First Posted: October 21, 2009
Last Update Posted: October 26, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Onyx Therapeutics, Inc.
Information provided by (Responsible Party):
University of Arkansas
This is a compassionate use, open-label, IND study for the purpose of providing carfilzomib to patients with relapsed or resistant refractory multiple myeloma.

Condition Intervention
Multiple Myeloma Drug: Carfilzomib

Study Type: Expanded Access     What is Expanded Access?
Official Title: Compassionate Use Study of Carfilzomib for Patients With Relapsing or Resistant Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by University of Arkansas:

Study Start Date: November 2009
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Carfilzomib

    Carfilzomib (20mg/m2) IV push to be given at maximum rate of 10ml/minute on Days 1 and Day 2 of Cycle 1 only.

    Carfilzomib (27mg/m2) IV bolus to be given at maximum rate of 10ml/minute on Day 8, 9, 15, and 16 of Cycle 1, then through Cycle 2 and beyond if initial dosing with 20mg/m2 tolerated.

    For patients who tolerated 27mg/m2 through cycle 2 Days 1 and 2, Carfilzomib dose may be escalated to 36mg/m2 on days 8, 9, 15 and 16 of cycle 2. If tolerated, subsequent cycles will utilize 36mg/m2.

Detailed Description:

The protocol has been designed for relapsing or refractory multiple myeloma patients. A maximum of 30 patients may be treated on this protocol.

Since this is a compassionate use study of an investigational agent, the size is determined by agreement with the manufacturer of carfilzomib. Therefore, the time period for enrollment and accrual number will be limited to N=30.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants must have histologically documented multiple myeloma which is relapsing or resistant after stem cell transplantation, or when other conventional therapies have failed or are contraindicated
  • Serum creatinine < 3.0 mg/dL OR calculated creatinine clearance >15 mL/min calculated or measured clearance is ≥15 mL/min
  • ANC > 1000/mm3 (may be supported with growth factors)
  • Platelet count > 30,000/mm3 (may receive transfusion)
  • Female participant of child-bearing potential has agreed to use dual methods of contraception for the duration of the study
  • Male participant has agreed to use a barrier method of contraception if sexually active with a female of child-bearing potential
  • Patients must have signed and IRB-approved written informed consent form and demonstrate willingness to meet follow-up schedule and study procedure obligations

Exclusion Criteria:

  • Active infection requiring systemic treatment
  • Requires concomitant use of approved or investigative anticancer therapeutic treatment with activity against multiple myeloma, other than dexamethasone
  • Concomitant use of other investigative agents (e.g., antibiotics or antiemetics)
  • Pregnant or breast-feeding
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00999414

United States, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
Sponsors and Collaborators
University of Arkansas
Onyx Therapeutics, Inc.
Principal Investigator: Bart Barlogie, MD, PhD University of Arkansas
  More Information

Additional Information:
Responsible Party: University of Arkansas
ClinicalTrials.gov Identifier: NCT00999414     History of Changes
Other Study ID Numbers: 111527
First Submitted: October 20, 2009
First Posted: October 21, 2009
Last Update Posted: October 26, 2015
Last Verified: October 2015

Keywords provided by University of Arkansas:

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases